10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

XLKD1 Antibody (N-term) Blocking Peptide

Synthetic peptide
Catalog # BP2015a

Specification

XLKD1 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession	Q9Y5Y7
Other Accession	NP_006682

XLKD1 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 10894

Other Names
Lymphatic vessel endothelial hyaluronic acid receptor 1, LYVE-1, Cell surface retention sequence-binding protein 1, CRSBP-1, Extracellular link domain-containing protein 1, Hyaluronic acid receptor, LYVE1, CRSBP1, HAR, XLKD1

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP2015a was selected from the N-term region of human XLKD1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

XLKD1 Antibody (N-term) Blocking Peptide - Protein Information

Name LYVE1

Synonyms CRSBP1, HAR, XLKD1

Function
Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes (PubMed:10037799). Binds to pericelluar hyaluronan matrices deposited on the

surface of leukocytes and facilitates cell adhesion and migration through lymphatic endothelium (PubMed:26823460).

Cellular Location
Cell membrane; Single-pass type I membrane protein. Note=Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans- Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface Localizes at cell-cell junctions

Tissue Location
Mainly expressed in endothelial cells lining lymphatic vessels.

XLKD1 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

XLKD1 Antibody (N-term) Blocking Peptide - Images

XLKD1 Antibody (N-term) Blocking Peptide - Background

One of the key groups of molecules regulating leukocyte and tumour cell migration is the glycosaminoglycan hyaluronan (HA). In inflammation, the exit of leukocytes across vascular endothelium to the underlying tissues involves interactions with cell surface lectin-like receptors on the leukocytes that bind HA on the lumenal surface of the endothelium. During normal tissue homeostasis and after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. Lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 is a major receptor for HA on the lymph vessel wall. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumour cells to lymph nodes.

XLKD1 Antibody (N-term) Blocking Peptide - References

Jackson, D.G., Trends Cardiovasc. Med. 13(1):1-7 (2003).Cursiefen, C., et al., Invest. Ophthalmol. Vis. Sci. 43(7):2127-2135 (2002).Cunnick, G.H., et al., Biochem. Biophys. Res. Commun. 288(4):1043-1046 (2001).Mouta Carreira, C., et al., Cancer Res. 61(22):8079-8084 (2001).Banerji, S., et al., J. Cell Biol. 144(4):789-801 (1999).